fb-pixel tracker
News

University of Arizona Cancer Center and Banner–University Medical Center Tucson Join the Precision Oncology Alliance Powered by Caris Life Sciences

Clinical Partners Join Alliance to Advance Precision Medicine in Oncology IRVING, Texas, July 30, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that the University of Arizona Cancer Center (UACC) and its clinical partner Banner – University Medical Center Tucson (Banner – … Continued

Caris Life Sciences Expands Management Team

Meeting the needs of a complex and growing market Brian Brille, experienced financial services executive joins as Vice Chairman, leading corporate and business development, M&A and capital markets Seasoned healthcare executives Michael Sullivan and Nicholas Nelson appointed as Chief Commercial Officer and Chief Business Officer, respectively IRVING, Tex., June 26, 2018 – Caris Life Sciences®, … Continued

Caris Life Sciences Presents Data Demonstrating the Ability of ADAPT Biotargeting System to Identify Responders and Non-Responders in a Phase III Pancreatic Cancer Study

Leveraging ADAPT Biotargeting System would have significantly increased the probability of success Data presented at the ESMO World Congress on Gastrointestinal Cancer 2018 IRVING, Tex., June 21, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced new data supporting the use of its … Continued

Bloomberg: Genetic-Sequencing Firm CEO With Jack Welch Aura Mulls New IPO

The following article appeared in Bloomberg: Genetic-Sequencing Firm CEO With Jack Welch Aura Mulls New IPO. Cristin Flanagan. June 6, 2018. David Halbert says he never missed or lowered his forecasts as the former head of a publicly traded company and grew earnings per share for investors quarter after quarter. Immediately, one of the Street’s most celebrated … Continued

Caris Life Sciences Data Highlighted During ASCO Presentation Showing Cascading Effects of Tumor Repair Gene Mutations and Tumor Cell Phenotype

Caris’ robust database enables evaluation of more than 24,000 tumor specimens to identify correlations with mismatch repair gene mutations, other DNA repair gene mutations and tumor phenotypes Oral presentation at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting IRVING, Tex., June 4, 2018 – Caris Life Sciences®, a leading innovator in molecular science … Continued

Caris Life Sciences Announces First Ph.D. Recipient from Educational Collaboration with Arizona State University

Private Industry / Academic Collaboration Fosters Real-World Innovative Research IRVING, Texas, May 22, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that its first employee has received his Ph.D. from a collaborative research program with Arizona State University (ASU). The Molecular and … Continued

Caris Life Sciences to Present New Molecular Findings at the 2018 ASCO Annual Meeting

Caris Data Further Advances Molecular Understandings of Cancer to Enable the Delivery of Precision Medicine IRVING, Tex., May 21, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of 10 abstracts, including one oral presentation, by the American Society of Clinical … Continued

Piedmont Cancer Joins Caris Life Sciences’ Precision Oncology Alliance

Piedmont Cancer becomes the 22nd institution to join the Precision Oncology Alliance IRVING, Texas, April 24, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced that Piedmont Cancer has joined Caris’ Precision Oncology Alliance (POA) as its 22nd member and will work with … Continued

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Data featured in Nature Communications showed ADAPT Biotargeting System significantly out-performed industry standard HER2 testing IRVING, Texas, March 23, 2018 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System (ADAPT) significantly out-performed … Continued

1 2 3 17

About Our News

Search to find the latest new about Caris Molecular Intelligence®, sign up for news alerts, and be sure to follow us on social media.